A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca’s experimental drug camizestrant significantly reduced the risk of disease progression or death in patients with advanced hormone receptor-positive, HER2-negative breast cancer by 56%, when prescribed based on early blood test results rather than visible tumor growth, experts announced Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The international trial marks a major shift in cancer treatment strategy by using liquid biopsy—a blood test that detects ESR1 gene mutations indicating early resistance to standard hormone therapies. Camizestrant, a selective estrogen receptor degrader (SERD), was shown to be effective in patients with early treatment resistance, even before tumors could be detected via imaging.
“This is going to be very impactful for our patients,” said Dr. Hope Rugo, head of breast medical oncology at City of Hope, California. “We’re staying ahead of the curve rather than reacting after the disease has already progressed,” added Dr. Eleonora Teplinsky, another ASCO expert.
The Phase 3 clinical trial involved 3,256 women, all previously treated with aromatase inhibitors and CDK4/6 inhibitors like Pfizer’s Ibrance or Novartis’ Kisqali. Among them, 315 women who developed ESR1 mutations were selected for a randomized trial. Those who switched to camizestrant plus CDK4/6 inhibitors experienced a median 16 months of progression-free survival compared to 9.2 months in the control group that continued standard therapy.
Camizestrant is not yet FDA-approved, but based on these findings, it may soon be adopted as part of a new treatment paradigm for early intervention in breast cancer progression.
AstraZeneca CEO Pascal Soriot acknowledged that integrating liquid biopsy into routine practice would initially be challenging but emphasized it as the future of cancer care.
In a separate announcement at the same ASCO meeting, another AstraZeneca drug, Imfinzi (durvalumab), showed promise in improving outcomes for early-stage stomach and esophageal cancer patients. When added to chemotherapy before and after surgery, Imfinzi reduced the risk of cancer recurrence, progression, or death by 29%.
Both sets of results were published in the New England Journal of Medicine and are expected to have lasting implications for the future of oncology.
Residents of villages in eastern Indonesia hit by a deadly earthquake that killed at least 54 people were awaiting...
South Korea's presidential Blue House said on Monday it was reviewing U.S. President Donald Trump's comments on scaling back joint military...
Shipping through the Strait of Hormuz slowed to a near standstill over the weekend, with five commodity vessels transiting Saturday and none on Sun...
At least 11 people were killed in Israeli strikes on southern Lebanon on Saturday, among the deadliest since a June ceasefire. Meanwhile, Qatar denied holding Iranian pilots. It said it had found the remains of one pilot after an airspace violation and had contacted Iran to coordinate a handover.
A wildfire in Croatia driven by strong winds descended on the tourist town of Omis overnight, engulfing houses, forcing about 1,000 people to evacuate to safety and injuring dozens, fire brigade and health officials said on Friday.
U.S. President Donald Trump's threats to make the Strait of Hormuz part of U.S. territory have been mocked by Iran's Deputy Foreign Minister, Kazem Gharibabadi, who said the sea passage "cannot be seized by tweet."
Russia and Ukraine traded large-scale overnight attacks targeting energy, industrial and military facilities on Saturday, with a three-month-old baby killed and 11 people injured in a Russian drone strike on a residential building in Ukraine’s Dnipropetrovsk region.
For fishermen along Pakistan’s southwestern coast, the consequences of the U.S.-Iran conflict are being felt far from the battlefield.
The Democratic Republic of Congo says the number of confirmed Ebola cases has risen to nearly 4,500, including more than 2,060 deaths. Delayed detection, weak surveillance, funding shortages and conflict have allowed the virus to spread faster than in any previous epidemic at the same stage.
Australia warned on Monday (3 August) of a wider spread of H5N1 bird flu after its first confirmed mass mortality event among seabirds killed about 50 greater crested terns off the coast of South Australia, south of Adelaide.
Cancer patients in Sudan are struggling to access life-saving treatment as soaring medication costs, power shortages and damaged hospital infrastructure deepen the country's healthcare crisis after more than three years of war.
The world risks a resurgence of the HIV epidemic after international funding fell by nearly a fifth last year, according to a new report from UNAIDS, which warned that decades of progress against the disease could be reversed without renewed global support.
A global shift towards healthier diets, more efficient farming and reduced food waste could cut greenhouse gas emissions from agriculture-related land-use change by 85% by 2050, according to a study published last week in the journal Nature.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment